Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

23andMe is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, casting doubt on its deal with Regeneron Pharmaceuticals.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron is paying Hansoh $80 million upfront for a phase 3-stage GLP-1/GIP agonist the companies believe can hold its own against Lilly’s Zepbound.

The potential acquisition makes Regeneron interesting, but it isn't a reason to buy the stock now. While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals has announced it will acquire 23andMe, the once high-flying consumer DNA testing company, for $256 million through a bankruptcy auction.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.